Loading…

Intrinsic signaling pathways modulate targeted protein degradation

Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target BRD4 and related neosubstrates BRD2/3 and CDK9...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2024-07, Vol.15 (1), p.5379-14, Article 5379
Main Authors: Mori, Yuki, Akizuki, Yoshino, Honda, Rikuto, Takao, Miyu, Tsuchimoto, Ayaka, Hashimoto, Sota, Iio, Hiroaki, Kato, Masakazu, Kaiho-Soma, Ai, Saeki, Yasushi, Hamazaki, Jun, Murata, Shigeo, Ushijima, Toshikazu, Hattori, Naoko, Ohtake, Fumiaki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c422t-673a14283eb4090cd5671123a30ad3667c48bfc3ca5b6aaf10a373598f272c0b3
container_end_page 14
container_issue 1
container_start_page 5379
container_title Nature communications
container_volume 15
creator Mori, Yuki
Akizuki, Yoshino
Honda, Rikuto
Takao, Miyu
Tsuchimoto, Ayaka
Hashimoto, Sota
Iio, Hiroaki
Kato, Masakazu
Kaiho-Soma, Ai
Saeki, Yasushi
Hamazaki, Jun
Murata, Shigeo
Ushijima, Toshikazu
Hattori, Naoko
Ohtake, Fumiaki
description Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target BRD4 and related neosubstrates BRD2/3 and CDK9 induced by CRL2 VHL - or CRL4 CRBN -based PROTACs. The chemicals identified as degradation enhancers include inhibitors of cellular signaling pathways such as poly-ADP ribosylation (PARG inhibitor PDD00017273), unfolded protein response (PERK inhibitor GSK2606414), and protein stabilization (HSP90 inhibitor luminespib). Mechanistically, PARG inhibition promotes TRIP12-mediated K29/K48-linked branched ubiquitylation of BRD4 by facilitating chromatin dissociation of BRD4 and formation of the BRD4–PROTAC–CRL2 VHL ternary complex; by contrast, HSP90 inhibition promotes BRD4 degradation after the ubiquitylation step. Consequently, these signal inhibitors sensitize cells to the PROTAC-induced apoptosis. These results suggest that various cell-intrinsic signaling pathways spontaneously counteract chemically induced target degradation at multiple steps, which could be liberated by specific inhibitors. Targeted protein degradation harnessing the ubiquitin system is a groundbreaking modality in drug discovery. Here, the authors identify cellular signaling pathways, such as PARG, PERK, or HSP90, that modulate the targeted degradation of the anticancer targets such as BRD4 induced by PROTACs.
doi_str_mv 10.1038/s41467-024-49519-z
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4f25f96a86114608b7624ec4158746a7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4f25f96a86114608b7624ec4158746a7</doaj_id><sourcerecordid>3075376344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-673a14283eb4090cd5671123a30ad3667c48bfc3ca5b6aaf10a373598f272c0b3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EolXpH2CBIrFhE_DbzgpBxWOkSt20a-vGcVKPMvZgO6D212MmpbQs6o0t33M_X5-D0GuC3xPM9IfMCZeqxZS3vBOka2-foWOKOWmJouz5g_MROs15i-tiHdGcv0RHTHdCYkGP0edNKMmH7G2T_RRg9mFq9lCuf8FNbnZxWGYorimQJlfc0OxTLM6HZnBTggGKj-EVejHCnN3p3X6Crr5-uTz73p5ffNucfTpvLae0tFIxIJxq5nqOO2wHIRUhlAHDMDApleW6Hy2zIHoJMBIMTDHR6ZEqanHPTtBm5Q4Rtmaf_A7SjYngzeEipslAKt7OzvCRirGToCWpLmHdK0m5s5wIrbgEVVkfV9Z-6XdusK66APMj6ONK8Ndmij9NnZhiInUlvLsjpPhjcbmYnc_WzTMEF5dsGFaCKck4r9K3_0m3cUnV64OKa00Uk1VFV5VNMefkxvtpCDZ_Ijdr5KZGbg6Rm9va9ObhP-5b_gZcBWwV5FoKk0v_3n4C-xsrxrZg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3074881736</pqid></control><display><type>article</type><title>Intrinsic signaling pathways modulate targeted protein degradation</title><source>Publicly Available Content Database</source><source>Nature</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Mori, Yuki ; Akizuki, Yoshino ; Honda, Rikuto ; Takao, Miyu ; Tsuchimoto, Ayaka ; Hashimoto, Sota ; Iio, Hiroaki ; Kato, Masakazu ; Kaiho-Soma, Ai ; Saeki, Yasushi ; Hamazaki, Jun ; Murata, Shigeo ; Ushijima, Toshikazu ; Hattori, Naoko ; Ohtake, Fumiaki</creator><creatorcontrib>Mori, Yuki ; Akizuki, Yoshino ; Honda, Rikuto ; Takao, Miyu ; Tsuchimoto, Ayaka ; Hashimoto, Sota ; Iio, Hiroaki ; Kato, Masakazu ; Kaiho-Soma, Ai ; Saeki, Yasushi ; Hamazaki, Jun ; Murata, Shigeo ; Ushijima, Toshikazu ; Hattori, Naoko ; Ohtake, Fumiaki</creatorcontrib><description>Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target BRD4 and related neosubstrates BRD2/3 and CDK9 induced by CRL2 VHL - or CRL4 CRBN -based PROTACs. The chemicals identified as degradation enhancers include inhibitors of cellular signaling pathways such as poly-ADP ribosylation (PARG inhibitor PDD00017273), unfolded protein response (PERK inhibitor GSK2606414), and protein stabilization (HSP90 inhibitor luminespib). Mechanistically, PARG inhibition promotes TRIP12-mediated K29/K48-linked branched ubiquitylation of BRD4 by facilitating chromatin dissociation of BRD4 and formation of the BRD4–PROTAC–CRL2 VHL ternary complex; by contrast, HSP90 inhibition promotes BRD4 degradation after the ubiquitylation step. Consequently, these signal inhibitors sensitize cells to the PROTAC-induced apoptosis. These results suggest that various cell-intrinsic signaling pathways spontaneously counteract chemically induced target degradation at multiple steps, which could be liberated by specific inhibitors. Targeted protein degradation harnessing the ubiquitin system is a groundbreaking modality in drug discovery. Here, the authors identify cellular signaling pathways, such as PARG, PERK, or HSP90, that modulate the targeted degradation of the anticancer targets such as BRD4 induced by PROTACs.</description><identifier>ISSN: 2041-1723</identifier><identifier>EISSN: 2041-1723</identifier><identifier>DOI: 10.1038/s41467-024-49519-z</identifier><identifier>PMID: 38956052</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/1 ; 13/89 ; 631/45/474/582 ; 631/80/474/2073 ; 631/92/458/582 ; 82/58 ; 82/83 ; Apoptosis ; Apoptosis - drug effects ; Biodegradation ; Bromodomain Containing Proteins ; Cancer ; Cell Cycle Proteins - metabolism ; Cell Line, Tumor ; Chromatin ; Cyclin-Dependent Kinase 9 - antagonists &amp; inhibitors ; Cyclin-Dependent Kinase 9 - metabolism ; Degradation ; Drug discovery ; HSP90 Heat-Shock Proteins - metabolism ; Hsp90 protein ; Humanities and Social Sciences ; Humans ; Inhibitors ; multidisciplinary ; Nuclear Proteins - genetics ; Nuclear Proteins - metabolism ; Protein folding ; Proteins ; Proteolysis - drug effects ; Regulatory mechanisms (biology) ; Ribosylation ; Science ; Science (multidisciplinary) ; Signal transduction ; Signal Transduction - drug effects ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Ubiquitin ; Ubiquitination</subject><ispartof>Nature communications, 2024-07, Vol.15 (1), p.5379-14, Article 5379</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c422t-673a14283eb4090cd5671123a30ad3667c48bfc3ca5b6aaf10a373598f272c0b3</cites><orcidid>0000-0002-3177-3503 ; 0000-0002-8590-6172 ; 0000-0002-9202-5453 ; 0000-0002-7145-3424 ; 0000-0003-3405-7817</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3074881736/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3074881736?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38956052$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mori, Yuki</creatorcontrib><creatorcontrib>Akizuki, Yoshino</creatorcontrib><creatorcontrib>Honda, Rikuto</creatorcontrib><creatorcontrib>Takao, Miyu</creatorcontrib><creatorcontrib>Tsuchimoto, Ayaka</creatorcontrib><creatorcontrib>Hashimoto, Sota</creatorcontrib><creatorcontrib>Iio, Hiroaki</creatorcontrib><creatorcontrib>Kato, Masakazu</creatorcontrib><creatorcontrib>Kaiho-Soma, Ai</creatorcontrib><creatorcontrib>Saeki, Yasushi</creatorcontrib><creatorcontrib>Hamazaki, Jun</creatorcontrib><creatorcontrib>Murata, Shigeo</creatorcontrib><creatorcontrib>Ushijima, Toshikazu</creatorcontrib><creatorcontrib>Hattori, Naoko</creatorcontrib><creatorcontrib>Ohtake, Fumiaki</creatorcontrib><title>Intrinsic signaling pathways modulate targeted protein degradation</title><title>Nature communications</title><addtitle>Nat Commun</addtitle><addtitle>Nat Commun</addtitle><description>Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target BRD4 and related neosubstrates BRD2/3 and CDK9 induced by CRL2 VHL - or CRL4 CRBN -based PROTACs. The chemicals identified as degradation enhancers include inhibitors of cellular signaling pathways such as poly-ADP ribosylation (PARG inhibitor PDD00017273), unfolded protein response (PERK inhibitor GSK2606414), and protein stabilization (HSP90 inhibitor luminespib). Mechanistically, PARG inhibition promotes TRIP12-mediated K29/K48-linked branched ubiquitylation of BRD4 by facilitating chromatin dissociation of BRD4 and formation of the BRD4–PROTAC–CRL2 VHL ternary complex; by contrast, HSP90 inhibition promotes BRD4 degradation after the ubiquitylation step. Consequently, these signal inhibitors sensitize cells to the PROTAC-induced apoptosis. These results suggest that various cell-intrinsic signaling pathways spontaneously counteract chemically induced target degradation at multiple steps, which could be liberated by specific inhibitors. Targeted protein degradation harnessing the ubiquitin system is a groundbreaking modality in drug discovery. Here, the authors identify cellular signaling pathways, such as PARG, PERK, or HSP90, that modulate the targeted degradation of the anticancer targets such as BRD4 induced by PROTACs.</description><subject>13/1</subject><subject>13/89</subject><subject>631/45/474/582</subject><subject>631/80/474/2073</subject><subject>631/92/458/582</subject><subject>82/58</subject><subject>82/83</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Biodegradation</subject><subject>Bromodomain Containing Proteins</subject><subject>Cancer</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Chromatin</subject><subject>Cyclin-Dependent Kinase 9 - antagonists &amp; inhibitors</subject><subject>Cyclin-Dependent Kinase 9 - metabolism</subject><subject>Degradation</subject><subject>Drug discovery</subject><subject>HSP90 Heat-Shock Proteins - metabolism</subject><subject>Hsp90 protein</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>multidisciplinary</subject><subject>Nuclear Proteins - genetics</subject><subject>Nuclear Proteins - metabolism</subject><subject>Protein folding</subject><subject>Proteins</subject><subject>Proteolysis - drug effects</subject><subject>Regulatory mechanisms (biology)</subject><subject>Ribosylation</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><subject>Ubiquitin</subject><subject>Ubiquitination</subject><issn>2041-1723</issn><issn>2041-1723</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUtv1DAUhS0EolXpH2CBIrFhE_DbzgpBxWOkSt20a-vGcVKPMvZgO6D212MmpbQs6o0t33M_X5-D0GuC3xPM9IfMCZeqxZS3vBOka2-foWOKOWmJouz5g_MROs15i-tiHdGcv0RHTHdCYkGP0edNKMmH7G2T_RRg9mFq9lCuf8FNbnZxWGYorimQJlfc0OxTLM6HZnBTggGKj-EVejHCnN3p3X6Crr5-uTz73p5ffNucfTpvLae0tFIxIJxq5nqOO2wHIRUhlAHDMDApleW6Hy2zIHoJMBIMTDHR6ZEqanHPTtBm5Q4Rtmaf_A7SjYngzeEipslAKt7OzvCRirGToCWpLmHdK0m5s5wIrbgEVVkfV9Z-6XdusK66APMj6ONK8Ndmij9NnZhiInUlvLsjpPhjcbmYnc_WzTMEF5dsGFaCKck4r9K3_0m3cUnV64OKa00Uk1VFV5VNMefkxvtpCDZ_Ijdr5KZGbg6Rm9va9ObhP-5b_gZcBWwV5FoKk0v_3n4C-xsrxrZg</recordid><startdate>20240702</startdate><enddate>20240702</enddate><creator>Mori, Yuki</creator><creator>Akizuki, Yoshino</creator><creator>Honda, Rikuto</creator><creator>Takao, Miyu</creator><creator>Tsuchimoto, Ayaka</creator><creator>Hashimoto, Sota</creator><creator>Iio, Hiroaki</creator><creator>Kato, Masakazu</creator><creator>Kaiho-Soma, Ai</creator><creator>Saeki, Yasushi</creator><creator>Hamazaki, Jun</creator><creator>Murata, Shigeo</creator><creator>Ushijima, Toshikazu</creator><creator>Hattori, Naoko</creator><creator>Ohtake, Fumiaki</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7ST</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>SOI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3177-3503</orcidid><orcidid>https://orcid.org/0000-0002-8590-6172</orcidid><orcidid>https://orcid.org/0000-0002-9202-5453</orcidid><orcidid>https://orcid.org/0000-0002-7145-3424</orcidid><orcidid>https://orcid.org/0000-0003-3405-7817</orcidid></search><sort><creationdate>20240702</creationdate><title>Intrinsic signaling pathways modulate targeted protein degradation</title><author>Mori, Yuki ; Akizuki, Yoshino ; Honda, Rikuto ; Takao, Miyu ; Tsuchimoto, Ayaka ; Hashimoto, Sota ; Iio, Hiroaki ; Kato, Masakazu ; Kaiho-Soma, Ai ; Saeki, Yasushi ; Hamazaki, Jun ; Murata, Shigeo ; Ushijima, Toshikazu ; Hattori, Naoko ; Ohtake, Fumiaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-673a14283eb4090cd5671123a30ad3667c48bfc3ca5b6aaf10a373598f272c0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>13/1</topic><topic>13/89</topic><topic>631/45/474/582</topic><topic>631/80/474/2073</topic><topic>631/92/458/582</topic><topic>82/58</topic><topic>82/83</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Biodegradation</topic><topic>Bromodomain Containing Proteins</topic><topic>Cancer</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Chromatin</topic><topic>Cyclin-Dependent Kinase 9 - antagonists &amp; inhibitors</topic><topic>Cyclin-Dependent Kinase 9 - metabolism</topic><topic>Degradation</topic><topic>Drug discovery</topic><topic>HSP90 Heat-Shock Proteins - metabolism</topic><topic>Hsp90 protein</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>multidisciplinary</topic><topic>Nuclear Proteins - genetics</topic><topic>Nuclear Proteins - metabolism</topic><topic>Protein folding</topic><topic>Proteins</topic><topic>Proteolysis - drug effects</topic><topic>Regulatory mechanisms (biology)</topic><topic>Ribosylation</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><topic>Ubiquitin</topic><topic>Ubiquitination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mori, Yuki</creatorcontrib><creatorcontrib>Akizuki, Yoshino</creatorcontrib><creatorcontrib>Honda, Rikuto</creatorcontrib><creatorcontrib>Takao, Miyu</creatorcontrib><creatorcontrib>Tsuchimoto, Ayaka</creatorcontrib><creatorcontrib>Hashimoto, Sota</creatorcontrib><creatorcontrib>Iio, Hiroaki</creatorcontrib><creatorcontrib>Kato, Masakazu</creatorcontrib><creatorcontrib>Kaiho-Soma, Ai</creatorcontrib><creatorcontrib>Saeki, Yasushi</creatorcontrib><creatorcontrib>Hamazaki, Jun</creatorcontrib><creatorcontrib>Murata, Shigeo</creatorcontrib><creatorcontrib>Ushijima, Toshikazu</creatorcontrib><creatorcontrib>Hattori, Naoko</creatorcontrib><creatorcontrib>Ohtake, Fumiaki</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Environment Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Nature communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mori, Yuki</au><au>Akizuki, Yoshino</au><au>Honda, Rikuto</au><au>Takao, Miyu</au><au>Tsuchimoto, Ayaka</au><au>Hashimoto, Sota</au><au>Iio, Hiroaki</au><au>Kato, Masakazu</au><au>Kaiho-Soma, Ai</au><au>Saeki, Yasushi</au><au>Hamazaki, Jun</au><au>Murata, Shigeo</au><au>Ushijima, Toshikazu</au><au>Hattori, Naoko</au><au>Ohtake, Fumiaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intrinsic signaling pathways modulate targeted protein degradation</atitle><jtitle>Nature communications</jtitle><stitle>Nat Commun</stitle><addtitle>Nat Commun</addtitle><date>2024-07-02</date><risdate>2024</risdate><volume>15</volume><issue>1</issue><spage>5379</spage><epage>14</epage><pages>5379-14</pages><artnum>5379</artnum><issn>2041-1723</issn><eissn>2041-1723</eissn><abstract>Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target BRD4 and related neosubstrates BRD2/3 and CDK9 induced by CRL2 VHL - or CRL4 CRBN -based PROTACs. The chemicals identified as degradation enhancers include inhibitors of cellular signaling pathways such as poly-ADP ribosylation (PARG inhibitor PDD00017273), unfolded protein response (PERK inhibitor GSK2606414), and protein stabilization (HSP90 inhibitor luminespib). Mechanistically, PARG inhibition promotes TRIP12-mediated K29/K48-linked branched ubiquitylation of BRD4 by facilitating chromatin dissociation of BRD4 and formation of the BRD4–PROTAC–CRL2 VHL ternary complex; by contrast, HSP90 inhibition promotes BRD4 degradation after the ubiquitylation step. Consequently, these signal inhibitors sensitize cells to the PROTAC-induced apoptosis. These results suggest that various cell-intrinsic signaling pathways spontaneously counteract chemically induced target degradation at multiple steps, which could be liberated by specific inhibitors. Targeted protein degradation harnessing the ubiquitin system is a groundbreaking modality in drug discovery. Here, the authors identify cellular signaling pathways, such as PARG, PERK, or HSP90, that modulate the targeted degradation of the anticancer targets such as BRD4 induced by PROTACs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38956052</pmid><doi>10.1038/s41467-024-49519-z</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-3177-3503</orcidid><orcidid>https://orcid.org/0000-0002-8590-6172</orcidid><orcidid>https://orcid.org/0000-0002-9202-5453</orcidid><orcidid>https://orcid.org/0000-0002-7145-3424</orcidid><orcidid>https://orcid.org/0000-0003-3405-7817</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2041-1723
ispartof Nature communications, 2024-07, Vol.15 (1), p.5379-14, Article 5379
issn 2041-1723
2041-1723
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4f25f96a86114608b7624ec4158746a7
source Publicly Available Content Database; Nature; PubMed Central; Springer Nature - nature.com Journals - Fully Open Access
subjects 13/1
13/89
631/45/474/582
631/80/474/2073
631/92/458/582
82/58
82/83
Apoptosis
Apoptosis - drug effects
Biodegradation
Bromodomain Containing Proteins
Cancer
Cell Cycle Proteins - metabolism
Cell Line, Tumor
Chromatin
Cyclin-Dependent Kinase 9 - antagonists & inhibitors
Cyclin-Dependent Kinase 9 - metabolism
Degradation
Drug discovery
HSP90 Heat-Shock Proteins - metabolism
Hsp90 protein
Humanities and Social Sciences
Humans
Inhibitors
multidisciplinary
Nuclear Proteins - genetics
Nuclear Proteins - metabolism
Protein folding
Proteins
Proteolysis - drug effects
Regulatory mechanisms (biology)
Ribosylation
Science
Science (multidisciplinary)
Signal transduction
Signal Transduction - drug effects
Transcription Factors - genetics
Transcription Factors - metabolism
Ubiquitin
Ubiquitination
title Intrinsic signaling pathways modulate targeted protein degradation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A53%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intrinsic%20signaling%20pathways%20modulate%20targeted%20protein%20degradation&rft.jtitle=Nature%20communications&rft.au=Mori,%20Yuki&rft.date=2024-07-02&rft.volume=15&rft.issue=1&rft.spage=5379&rft.epage=14&rft.pages=5379-14&rft.artnum=5379&rft.issn=2041-1723&rft.eissn=2041-1723&rft_id=info:doi/10.1038/s41467-024-49519-z&rft_dat=%3Cproquest_doaj_%3E3075376344%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-673a14283eb4090cd5671123a30ad3667c48bfc3ca5b6aaf10a373598f272c0b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3074881736&rft_id=info:pmid/38956052&rfr_iscdi=true